Biomarkers /
KRAS Mutation
Overview
KRAS Mutation is present in 14.73% of AACR GENIE cases, with colorectal adenocarcinoma, non-small cell lung carcinoma, pancreatic exocrine neoplasm, uterine corpus neoplasm, and ovarian neoplasm having the greatest prevalence [4].
Clinical Trials
KRAS Mutation serves as an inclusion eligibility criterion in 75 clinical trials, of which 63 are open and 12 are closed. Of the trials that contain KRAS Mutation as an inclusion criterion, 31 are phase 1 (22 open), 17 are phase 1/phase 2 (16 open), 24 are phase 2 (22 open), and 3 are phase 3 (3 open).
Trials with KRAS Mutation in the inclusion eligibility criteria most commonly target malignant solid tumor, non-small cell lung carcinoma, colorectal carcinoma, acute myeloid leukemia, and non-hodgkin lymphoma [5].
Trametinib, selumetinib, raf/mek serine/threonine kinase inhibitor ro5126766, abemaciclib, and everolimus are the most frequent therapies in trials with KRAS Mutation as an inclusion criteria [5].
Significance of KRAS Mutation in Diseases
Malignant Solid Tumor +
KRAS is mutated in 3.3% of malignant solid tumor patients with KRAS Mutation present in 3.08% of all malignant solid tumor patients [4].
KRAS Mutation is an inclusion criterion in 35 clinical trials for malignant solid tumor, of which 29 are open and 6 are closed. Of the trials that contain KRAS Mutation and malignant solid tumor as inclusion criteria, 20 are phase 1 (14 open), 7 are phase 1/phase 2 (7 open), and 8 are phase 2 (8 open) [5].
Selumetinib, everolimus, and olaparib are the most frequent therapies in trials for malignant solid tumor that contain KRAS Mutation [5].
Non-Small Cell Lung Carcinoma +
KRAS is mutated in 29.7% of non-small cell lung carcinoma patients with KRAS Mutation present in 29.05% of all non-small cell lung carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 27 clinical trials for non-small cell lung carcinoma, of which 23 are open and 4 are closed. Of the trials that contain KRAS Mutation and non-small cell lung carcinoma as inclusion criteria, 11 are phase 1 (9 open), 4 are phase 1/phase 2 (4 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [5].
Pemetrexed, pembrolizumab, and erlotinib are the most frequent therapies in trials for non-small cell lung carcinoma that contain KRAS Mutation [5].
Colorectal Carcinoma +
KRAS is mutated in 47.01% of colorectal carcinoma patients with KRAS Mutation present in 47.01% of all colorectal carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 17 clinical trials for colorectal carcinoma, of which 16 are open and 1 is closed. Of the trials that contain KRAS Mutation and colorectal carcinoma as inclusion criteria, 9 are phase 1 (8 open), 6 are phase 1/phase 2 (6 open), and 2 are phase 2 (2 open) [5].
Trametinib, cetuximab, and asn007 are the most frequent therapies in trials for colorectal carcinoma that contain KRAS Mutation [5].
Acute Myeloid Leukemia +
KRAS is mutated in 3.77% of acute myeloid leukemia patients with KRAS Mutation present in 3.77% of all acute myeloid leukemia patients [4].
KRAS Mutation is an inclusion criterion in 7 clinical trials for acute myeloid leukemia, of which 6 are open and 1 is closed. Of the trials that contain KRAS Mutation and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [5].
Allogeneic hematopoietic stem cell transplantation, busulfan, and fludarabine are the most frequent therapies in trials for acute myeloid leukemia that contain KRAS Mutation [5].
Pancreatic Carcinoma +
KRAS is mutated in 86.05% of pancreatic carcinoma patients with KRAS Mutation present in 85.75% of all pancreatic carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 6 clinical trials for pancreatic carcinoma, of which 6 are open and 0 are closed. Of the trials that contain KRAS Mutation and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].
Extended release flucytosine, trail receptor agonist abbv-621, and valproic acid are the most frequent therapies in trials for pancreatic carcinoma that contain KRAS Mutation [5].
Non-Hodgkin Lymphoma +
KRAS is mutated in 3.6% of non-hodgkin lymphoma patients with KRAS Mutation present in 3.6% of all non-hodgkin lymphoma patients [4].
KRAS Mutation is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain KRAS Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].
Ulixertinib, selumetinib, and antineoplastic immune cell are the most frequent therapies in trials for non-hodgkin lymphoma that contain KRAS Mutation [5].
Melanoma +
KRAS is mutated in 3.03% of melanoma patients with KRAS Mutation present in 2.51% of all melanoma patients [4].
KRAS Mutation is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain KRAS Mutation and melanoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [5].
Asn007, erk1/2 inhibitor ly3214996, and extended release flucytosine are the most frequent therapies in trials for melanoma that contain KRAS Mutation [5].
Myelodysplastic Syndromes +
KRAS is mutated in 1.35% of myelodysplastic syndromes patients with KRAS Mutation present in 1.35% of all myelodysplastic syndromes patients [4].
KRAS Mutation is an inclusion criterion in 5 clinical trials for myelodysplastic syndromes, of which 4 are open and 1 is closed. Of the trials that contain KRAS Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].
Allogeneic hematopoietic stem cell transplantation, busulfan, and fludarabine are the most frequent therapies in trials for myelodysplastic syndromes that contain KRAS Mutation [5].
Breast Carcinoma +
KRAS is mutated in 1.92% of breast carcinoma patients with KRAS Mutation present in 0.76% of all breast carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 5 are open and 0 are closed. Of the trials that contain KRAS Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Extended release flucytosine, vistusertib, and abemaciclib are the most frequent therapies in trials for breast carcinoma that contain KRAS Mutation [5].
Chronic Myelomonocytic Leukemia +
KRAS is mutated in 12.0% of chronic myelomonocytic leukemia patients with KRAS Mutation present in 12.0% of all chronic myelomonocytic leukemia patients [4].
KRAS Mutation is an inclusion criterion in 4 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain KRAS Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Busulfan, fludarabine, and allogeneic cd56-positive cd3-negative natural killer cells are the most frequent therapies in trials for chronic myelomonocytic leukemia that contain KRAS Mutation [5].
Multiple Myeloma +
KRAS Mutation is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Antineoplastic immune cell, raf/mek serine/threonine kinase inhibitor ro5126766, and abemaciclib are the most frequent therapies in trials for multiple myeloma that contain KRAS Mutation [5].
Pancreatic Ductal Adenocarcinoma +
KRAS is mutated in 80.0% of pancreatic ductal adenocarcinoma patients with KRAS Mutation present in 80.0% of all pancreatic ductal adenocarcinoma patients [4].
KRAS Mutation is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].
Asn007, erk1/2 inhibitor ly3214996, and abemaciclib are the most frequent therapies in trials for pancreatic ductal adenocarcinoma that contain KRAS Mutation [5].
Colorectal Adenocarcinoma +
KRAS is mutated in 44.19% of colorectal adenocarcinoma patients with KRAS Mutation present in 43.74% of all colorectal adenocarcinoma patients [4].
KRAS Mutation is an inclusion criterion in 3 clinical trials for colorectal adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].
Anti-gpa33/cd3 monoclonal antibody mgd007, vitamin c supplement, and dexamethasone are the most frequent therapies in trials for colorectal adenocarcinoma that contain KRAS Mutation [5].
Ovarian Carcinoma +
KRAS is mutated in 11.36% of ovarian carcinoma patients with KRAS Mutation present in 11.36% of all ovarian carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].
Extended release flucytosine, sra737, and vistusertib are the most frequent therapies in trials for ovarian carcinoma that contain KRAS Mutation [5].
Acute Lymphoblastic Leukemia +
KRAS is mutated in 9.87% of acute lymphoblastic leukemia patients with KRAS Mutation present in 9.87% of all acute lymphoblastic leukemia patients [4].
KRAS Mutation is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].
Antineoplastic immune cell, ect-001 expanded cord blood, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for acute lymphoblastic leukemia that contain KRAS Mutation [5].
Head And Neck Squamous Cell Carcinoma +
KRAS is mutated in 2.38% of head and neck squamous cell carcinoma patients with KRAS Mutation present in 1.65% of all head and neck squamous cell carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Ko-947 and sra737 are the most frequent therapies in trials for head and neck squamous cell carcinoma that contain KRAS Mutation [5].
Glioma +
KRAS is mutated in 0.81% of glioma patients with KRAS Mutation present in 0.81% of all glioma patients [4].
KRAS Mutation is an inclusion criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and glioma as inclusion criteria, 3 are phase 1/phase 2 (3 open) [5].
Cobimetinib and trametinib are the most frequent therapies in trials for glioma that contain KRAS Mutation [5].
Colon Carcinoma +
KRAS is mutated in 43.13% of colon carcinoma patients with KRAS Mutation present in 42.51% of all colon carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 2 clinical trials for colon carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].
Valproic acid and neratinib are the most frequent therapies in trials for colon carcinoma that contain KRAS Mutation [5].
Lung Adenocarcinoma +
KRAS is mutated in 32.99% of lung adenocarcinoma patients with KRAS Mutation present in 32.35% of all lung adenocarcinoma patients [4].
KRAS Mutation is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Ponatinib and trametinib are the most frequent therapies in trials for lung adenocarcinoma that contain KRAS Mutation [5].
Bladder Carcinoma +
KRAS is mutated in 6.76% of bladder carcinoma patients with KRAS Mutation present in 6.02% of all bladder carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for bladder carcinoma that contain KRAS Mutation [5].
Esophageal Carcinoma +
KRAS is mutated in 13.13% of esophageal carcinoma patients with KRAS Mutation present in 3.64% of all esophageal carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and esophageal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Palbociclib is the most frequent therapy in trials for esophageal carcinoma that contain KRAS Mutation [5].
Diffuse Large B-Cell Lymphoma +
KRAS is mutated in 1.49% of diffuse large B-cell lymphoma patients with KRAS Mutation present in 1.49% of all diffuse large B-cell lymphoma patients [4].
KRAS Mutation is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Antineoplastic immune cell, trail receptor agonist abbv-621, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for diffuse large B-cell lymphoma that contain KRAS Mutation [5].
Renal Cell Carcinoma +
KRAS is mutated in 1.07% of renal cell carcinoma patients with KRAS Mutation present in 1.07% of all renal cell carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Vistusertib, cabozantinib, and docetaxel are the most frequent therapies in trials for renal cell carcinoma that contain KRAS Mutation [5].
Neuroblastoma +
KRAS is mutated in 0.93% of neuroblastoma patients with KRAS Mutation present in 0.93% of all neuroblastoma patients [4].
KRAS Mutation is an inclusion criterion in 2 clinical trials for neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Cobimetinib is the most frequent therapy in trials for neuroblastoma that contain KRAS Mutation [5].
Neurofibromatosis Type 1 +
KRAS Mutation is an inclusion criterion in 2 clinical trials for neurofibromatosis type 1, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and neurofibromatosis type 1 as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].
Trametinib is the most frequent therapy in trials for neurofibromatosis type 1 that contain KRAS Mutation [5].
Endometrial Carcinoma +
KRAS is mutated in 20.89% of endometrial carcinoma patients with KRAS Mutation present in 20.0% of all endometrial carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Vistusertib and selumetinib are the most frequent therapies in trials for endometrial carcinoma that contain KRAS Mutation [5].
Cholangiocarcinoma +
KRAS is mutated in 16.45% of cholangiocarcinoma patients with KRAS Mutation present in 15.87% of all cholangiocarcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Vistusertib, adavosertib, and capivasertib are the most frequent therapies in trials for cholangiocarcinoma that contain KRAS Mutation [5].
Lung Carcinoma +
KRAS is mutated in 11.93% of lung carcinoma patients with KRAS Mutation present in 11.35% of all lung carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Vitamin c supplement is the most frequent therapy in trials for lung carcinoma that contain KRAS Mutation [5].
Malignant Ovarian Epithelial Tumor +
KRAS is mutated in 11.95% of malignant ovarian epithelial tumor patients with KRAS Mutation present in 8.37% of all malignant ovarian epithelial tumor patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1 (1 open) [5].
Paclitaxel and spleen tyrosine kinase inhibitor tak-659 are the most frequent therapies in trials for malignant ovarian epithelial tumor that contain KRAS Mutation [5].
Gastric Carcinoma +
KRAS is mutated in 11.87% of gastric carcinoma patients with KRAS Mutation present in 7.99% of all gastric carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Palbociclib is the most frequent therapy in trials for gastric carcinoma that contain KRAS Mutation [5].
Cancer +
KRAS is mutated in 6.57% of cancer patients with KRAS Mutation present in 6.57% of all cancer patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and cancer as inclusion criteria, 1 is phase 1 (0 open) [5].
Germ Cell Tumor +
KRAS is mutated in 16.67% of germ cell tumor patients with KRAS Mutation present in 5.56% of all germ cell tumor patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Palbociclib is the most frequent therapy in trials for germ cell tumor that contain KRAS Mutation [5].
Urothelial Carcinoma +
KRAS is mutated in 6.22% of urothelial carcinoma patients with KRAS Mutation present in 5.47% of all urothelial carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Thyroid Gland Carcinoma +
KRAS is mutated in 5.03% of thyroid gland carcinoma patients with KRAS Mutation present in 5.03% of all thyroid gland carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Vistusertib and selumetinib are the most frequent therapies in trials for thyroid gland carcinoma that contain KRAS Mutation [5].
Malignant Peripheral Nerve Sheath Tumor +
KRAS is mutated in 5.0% of malignant peripheral nerve sheath tumor patients with KRAS Mutation present in 5.0% of all malignant peripheral nerve sheath tumor patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Cobimetinib is the most frequent therapy in trials for malignant peripheral nerve sheath tumor that contain KRAS Mutation [5].
Squamous Cell Lung Carcinoma +
KRAS is mutated in 5.35% of squamous cell lung carcinoma patients with KRAS Mutation present in 4.53% of all squamous cell lung carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Vistusertib and selumetinib are the most frequent therapies in trials for squamous cell lung carcinoma that contain KRAS Mutation [5].
Papillary Renal Cell Carcinoma +
KRAS is mutated in 4.31% of papillary renal cell carcinoma patients with KRAS Mutation present in 4.31% of all papillary renal cell carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for papillary renal cell carcinoma that contain KRAS Mutation [5].
Poorly Differentiated Thyroid Gland Carcinoma +
KRAS is mutated in 4.31% of poorly differentiated thyroid gland carcinoma patients with KRAS Mutation present in 4.31% of all poorly differentiated thyroid gland carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in trials for poorly differentiated thyroid gland carcinoma that contain KRAS Mutation [5].
Mantle Cell Lymphoma +
KRAS is mutated in 3.7% of mantle cell lymphoma patients with KRAS Mutation present in 3.7% of all mantle cell lymphoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in trials for mantle cell lymphoma that contain KRAS Mutation [5].
Small Cell Lung Carcinoma +
KRAS is mutated in 3.97% of small cell lung carcinoma patients with KRAS Mutation present in 3.4% of all small cell lung carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in trials for small cell lung carcinoma that contain KRAS Mutation [5].
Rhabdomyosarcoma +
KRAS is mutated in 4.31% of rhabdomyosarcoma patients with KRAS Mutation present in 2.59% of all rhabdomyosarcoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Cobimetinib is the most frequent therapy in trials for rhabdomyosarcoma that contain KRAS Mutation [5].
Histiocytic And Dendritic Cell Neoplasm +
KRAS is mutated in 2.44% of histiocytic and dendritic cell neoplasm patients with KRAS Mutation present in 2.44% of all histiocytic and dendritic cell neoplasm patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Selumetinib is the most frequent therapy in trials for histiocytic and dendritic cell neoplasm that contain KRAS Mutation [5].
Thyroid Gland Follicular Carcinoma +
KRAS is mutated in 2.15% of thyroid gland follicular carcinoma patients with KRAS Mutation present in 2.15% of all thyroid gland follicular carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in trials for thyroid gland follicular carcinoma that contain KRAS Mutation [5].
Thyroid Gland Papillary Carcinoma +
KRAS is mutated in 2.02% of thyroid gland papillary carcinoma patients with KRAS Mutation present in 2.02% of all thyroid gland papillary carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in trials for thyroid gland papillary carcinoma that contain KRAS Mutation [5].
Lymphoma +
KRAS is mutated in 1.64% of lymphoma patients with KRAS Mutation present in 1.64% of all lymphoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for lymphoma that contain KRAS Mutation [5].
Sarcoma +
KRAS is mutated in 1.87% of sarcoma patients with KRAS Mutation present in 1.53% of all sarcoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for sarcoma that contain KRAS Mutation [5].
Chronic Myeloid Leukemia +
KRAS is mutated in 1.47% of chronic myeloid leukemia patients with KRAS Mutation present in 1.47% of all chronic myeloid leukemia patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Allogeneic cd56-positive cd3-negative natural killer cells, interleukin-2, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for chronic myeloid leukemia that contain KRAS Mutation [5].
Soft Tissue Sarcoma +
KRAS is mutated in 1.85% of soft tissue sarcoma patients with KRAS Mutation present in 1.15% of all soft tissue sarcoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Cobimetinib is the most frequent therapy in trials for soft tissue sarcoma that contain KRAS Mutation [5].
Glioblastoma +
KRAS is mutated in 1.67% of glioblastoma patients with KRAS Mutation present in 1.04% of all glioblastoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for glioblastoma that contain KRAS Mutation [5].
Head And Neck Carcinoma +
KRAS is mutated in 2.06% of head and neck carcinoma patients with KRAS Mutation present in 0.92% of all head and neck carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for head and neck carcinoma that contain KRAS Mutation [5].
Prostate Carcinoma +
KRAS is mutated in 1.1% of prostate carcinoma patients with KRAS Mutation present in 0.87% of all prostate carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Sra737 is the most frequent therapy in trials for prostate carcinoma that contain KRAS Mutation [5].
Gastrointestinal Stromal Tumor +
KRAS is mutated in 0.68% of gastrointestinal stromal tumor patients with KRAS Mutation present in 0.68% of all gastrointestinal stromal tumor patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (1 open) [5].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for gastrointestinal stromal tumor that contain KRAS Mutation [5].
Hepatocellular Carcinoma +
KRAS is mutated in 0.63% of hepatocellular carcinoma patients with KRAS Mutation present in 0.63% of all hepatocellular carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Clear Cell Renal Cell Carcinoma +
KRAS is mutated in 0.16% of clear cell renal cell carcinoma patients with KRAS Mutation present in 0.16% of all clear cell renal cell carcinoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for clear cell renal cell carcinoma that contain KRAS Mutation [5].
Anaplastic Astrocytoma +
KRAS is mutated in 2.99% of anaplastic astrocytoma patients [4].
KRAS Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for anaplastic astrocytoma that contain KRAS Mutation [5].
Double-Hit Lymphoma +
KRAS Mutation is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and double-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in trials for double-hit lymphoma that contain KRAS Mutation [5].
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +
KRAS Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].
Busulfan, fludarabine, and venetoclax are the most frequent therapies in trials for myelodysplastic/myeloproliferative neoplasm, unclassifiable that contain KRAS Mutation [5].
Peripheral T-Cell Lymphoma +
KRAS Mutation is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in trials for peripheral T-cell lymphoma that contain KRAS Mutation [5].
Peritoneal Mesothelioma +
KRAS Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for peritoneal mesothelioma that contain KRAS Mutation [5].
Pleural Mesothelioma +
KRAS Mutation is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for pleural mesothelioma that contain KRAS Mutation [5].
Refractory Anemia With Excess Blasts-2 +
KRAS Mutation is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and refractory anemia with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Binimetinib is the most frequent therapy in trials for refractory anemia with excess blasts-2 that contain KRAS Mutation [5].
Rhabdoid Tumor +
KRAS Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Cobimetinib is the most frequent therapy in trials for rhabdoid tumor that contain KRAS Mutation [5].
Schwannoma +
KRAS Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Cobimetinib is the most frequent therapy in trials for schwannoma that contain KRAS Mutation [5].
Secondary Acute Myeloid Leukemia +
KRAS Mutation is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].
Ect-001 expanded cord blood is the most frequent therapy in trials for secondary acute myeloid leukemia that contain KRAS Mutation [5].
Therapy-Related Acute Myeloid Leukemia +
KRAS Mutation is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].
Ect-001 expanded cord blood is the most frequent therapy in trials for therapy-related acute myeloid leukemia that contain KRAS Mutation [5].
Thymic Carcinoma +
KRAS Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in trials for thymic carcinoma that contain KRAS Mutation [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.